



LEPROSY RESEARCH INITIATIVE



Photo credits: Mario Schmitt / DAHW

ANNUAL REPORT 2024

CONTENTS

1	Foreword	3
2	About the Leprosy Research Initiative	4
3	Promoting, facilitating and funding high-quality leprosy research	5
3.1	Regular Grant cycle in 2024	5
3.2	RESILIENTD Grant cycle in 2024	6
3.3	Start of research projects	7
3.4	Monitoring of ongoing research projects	7
3.5	Geographical distribution research projects	8
3.6	Completed projects	8
4	Strengthening research capacity	9
4.1	LRI Spring Meeting – in-person event	9
4.2	Online highlights of LRI Spring Meeting event	10
4.3	Research capacity strengthening grant	10
4.2	Workshop on scientific writing	11
5	Facilitating translation of research results into policy and practice	11
5.1	Impact Assessment	11
5.2	Advancing leprosy and NTD impact through collaboration	12
5.3	Communications	13
6	Future perspectives	13
7	Our partners in 2024	14
8	Our team in 2024	14
8.1	Executives Group	14
8.2	Steering Committee	14
8.3	Scientific Review Committee	15
8.4	LRI Communications Committee (COCO)	15
8.5	LRI Secretariat	15
9	Reviewer acknowledgements	16
10	Financial narrative	17
11	Annual accounts	18
	Colophon	34

1 FOREWORD

As we reflect on the past year, I am pleased to share the remarkable progress and achievements of the Leprosy Research Initiative (LRI) in 2024. Our collective efforts have furthered our mission to advance research, foster collaboration, and work towards a future free from leprosy.

This year, seven research groups successfully launched their projects, spanning diverse countries and disciplines, while four new projects received prestigious LRI regular grants. We also hosted a blended scientific writing workshop, empowering LRI-funded early-career researchers with the essential skills needed to publish their findings and contribute to the global scientific community.

The in-person LRI Spring Meeting in the Netherlands brought together nearly 100 stakeholders, providing a platform for presenting the latest updates on LRI-funded research. Additionally, our online 'Highlights of LRI Spring Meeting' event allowed audiences worldwide to engage with selected projects. The LRI Executives Group, Steering Committee, and Scientific Review Committee convened in both Spring and Autumn, ensuring the continuous development and success of our initiatives.

Collaboration remained at the heart of our work as we supported the GPZL Zero Transmission Symposium in Norway, where experts discussed strategies to achieve the interruption of the transmission of *Mycobacterium leprae*. Additionally, we strengthened our research impact assessment by revising our progress report forms to better capture the diverse impact domains of the LRI supported research projects.

At the NNN Conference in Malaysia, we proudly presented our ongoing efforts to meaningfully involve persons affected by skin NTDs in research. Our communications strategy also saw significant growth, with our LinkedIn community expanding and continuous engagement with stakeholders in leprosy research through our Communications Committee.

The LRI-Anesvad Foundation RESILIENTD grant, dedicated to studying social determinants of skin NTDs in Sub-Saharan Africa, concluded its first selection cycle, awarding three exciting project proposals. Furthermore, we successfully launched two calls for research proposals, and we eagerly anticipate reviewing new submissions in the first quarter of 2025.

None of these accomplishments would have been possible without the unwavering dedication of our partners, committees, and research community. Your contributions have made 2024 a truly memorable year, and together, we are making meaningful strides towards our shared goal of a world without leprosy.

We look forward to another year of collaboration and progress in 2025!



Linda Hummel | Director

2 ABOUT THE LEPROSY RESEARCH INITIATIVE

The Leprosy Research Initiative (LRI) was launched in 2013 to boost scientific research in leprosy.

Our vision is **a world free of leprosy** and we aim to contribute to this vision by:

1. promoting, facilitating and funding high-quality leprosy research;
2. strengthening research capacity in endemic countries, and;
3. facilitating translation of research results into policy and practice.

An established joint research fund combined with an efficient, transparent and rigorous selection procedure and progress monitoring processes ensure scientifically high-quality and sustainable funding. Understanding training needs and providing opportunities for shared learning strengthen capacity in research. Through encouragement and monitoring of dissemination and uptake of study findings, we strive for a positive impact towards zero transmission, zero disability and zero exclusion.

The LRI is governed and managed by the following bodies:

Executives Group (EG): oversees strategy and is the decision-making authority; consists of the executive directors of the LRI Full Partners.

Steering Committee (SC): provides scientific guidance and reviews submitted letters of intent; consists of the research coordinators of the LRI Partners and an independent Chair.

Scientific Review Committee (SRC): assesses full proposals and project progress; consists of independent scientists.

Secretariat: provides grant management, administration and technical support, and partner management. The secretariat also organises and facilitates capacity strengthening, communication, meetings and events, and is based in Amsterdam, the Netherlands.

Following a priority-setting assessment, LRI stakeholders identified five main research priorities for 2020-2025:



To be eligible for LRI funding, projects should focus on one of these priorities. More details can be found in our [LRI Joint Research Policy 2020-2025](#).

3 PROMOTING, FACILITATING AND FUNDING HIGH-QUALITY LEPROSY RESEARCH

The annual regular call for research proposals consists of a two-stage application process; the submission of an initial Letter of Intent (LoI) outlining the study aim, envisaged method and indication of scope, budget and timeline, followed by a detailed proposal for selected applicants. We have developed a thorough review process using an online grant management system, that gives applicants the opportunity to improve their application based on the feedback from external reviewers resulting in the selection of the most promising proposals for high-quality and impactful leprosy research.

3.1 REGULAR GRANT CYCLE IN 2024

The submission and review process of applications started with the launching of the call for proposals in December 2023 (step 1), inviting research proposals across all five LRI research priorities.

After closing the submission deadline in January 2024, the Steering Committee (SC) met virtually in March to discuss their review of the 75 LoIs (step 2). Selected applicants (20) were invited to submit a full proposal (step 3), these were reviewed by external reviewers (step 4).

Their anonymous feedback was shared with the applicants which could be addressed in the rebuttal proposal (step 5).

Next, in the Autumn meetings, the Scientific Review Committee (SRC) reviewed the rebuttal proposals and recommended a selection of eight projects for funding, further discussed and ranked (seven) by the SC (step 6).

The final decision to accept four proposals for funding was made by the Executives Group (EG) in November (step 7) after which the research groups were informed.



3.2 RESILIENTD GRANT CYCLE IN 2024

In collaboration with Anesvad Foundation, a new call for proposals was launched in December 2023: the RESILIENTD grant, with a special focus on social determinants of skin NTDs in Sub-Saharan Africa. The acronym for 'REsearch on Social determinants of Leprosy and NTDs' reflects the resilience of communities affected by skin NTDs and resilience of researchers, donors and the wider public health stakeholders to eliminate NTDs.

The RESILIENTD grant cycle is facilitated by the LRI Secretariat, supported by LRI structures, and funded by Anesvad Foundation. Launched alongside the LRI Regular grant, the RESILIENTD call for proposals opened in December 2023 (Step 1). Following the submission deadline in January 2024, the Steering Committee (SC) convened virtually in March to review the 33 Letters of Intent (LoIs) (Step 2). Shortlisted candidates (nine) were invited to submit full proposals (Step 3), which were then evaluated by external reviewers (Step 4). Applicants received anonymous feedback, allowing them to refine their submissions in a rebuttal proposal (Step 5). In the autumn meetings, the Scientific Review Committee (SRC) assessed these rebuttal proposals and recommended a selection of four projects for funding, which SC members further reviewed and ranked (three) (Step 6). The final funding decisions were made Anesvad Foundation (Step 7), after which the three selected research teams were notified.

We deeply appreciate this strengthened partnership, which bolsters efforts in this vital research area. We eagerly anticipate supporting the launch of these impactful projects.



3.3 START OF RESEARCH PROJECTS

In addition, seven research projects made their start in 2024 – with a total budget of €1,269,777. These grants had been awarded at the end of 2023, selected from 65 Letters of Intent out of which 19 full proposals (29%) were reviewed. The newly started projects were:

Title	Lead applicant <i>Host institution</i>	Country	Budget	Co-funding
			Duration	
Seeking for immunological susceptibility markers for leprosy. Identification of SNPs in miRNAs binding sites and their role in immune response modulation in leprosy	Soriani <i>Universidade Federal de Minas Gerais</i>	Brazil	€186,584 48 months	
Use of handheld ultrasound for the early detection of leprosy and evaluation of its value as compared to existing diagnostic tests	Chaitanya Vedithi <i>ALM</i>	India, Nepal	€115,946 24 months	Turing Foundation
Establishing the effectiveness of a peer support approach based Basic Psychological Support for NTDs to address mental wellbeing, stigma and social participation of persons affected by leprosy and LF in Jharkhand, India	Agarwal <i>NLR India Foundation</i>	India	€206,666 28 months	
Capacity Building for Leprosy	Udo <i>TLM Nigeria</i>	Nigeria, India	€102,520 24 months	St. Francis Leprosy Guild
Addressing Leprosy Trauma Using the Traumatic Stress Relief Programme: An exploratory Trial with Persons with Lived Experience in Addis Ababa, Ethiopia	Kaptan <i>Erq Ma'ed Media and Psychological Services</i>	Ethiopia	€136,780 30 months	
Contribution of Drug-resistance and <i>lepromatosis</i> to persistent leprosy transmission in parts of Africa	Braet <i>Institute of Tropical Medicine Antwerp</i>	Burundi, Cameroon, Congo, Ghana, Belgium	€320,815 48 months	Turing Foundation
Holistic investigation for environmental presence of <i>Mycobacterium leprae</i> and its implications in leprosy transmission through WASH and One Health approach	Srikantam <i>LEPRA Society-Blue Peter Public Health and Research Centre</i>	India	€200,466 36 months	Turing Foundation

3.4 MONITORING OF ONGOING RESEARCH PROJECTS

Grantees submit progress reports twice a year, in March and September, on the basis of which the progress of the [funded projects](#) is monitored.


The SRC assesses study progress and financial reporting and discusses these in their in-person Spring meeting (April 2024) and virtual Autumn meeting (October 2024), after which they provide recommendations to the EG on continuation of funding.

Approximately a third of the projects requested a no-cost extension, mainly due to unexpected delays, including delays in receiving ethical approvals, project management issues, enrolment challenges, and political instability. After SRC review, all requested extensions were accepted by the EG.

3.5 GEOGRAPHICAL DISTRIBUTION RESEARCH PROJECTS

The 45 LRI-funded projects active in 2024 were carried out in 24 countries across several continents. Multiple projects are ongoing in India (13), Nepal (7), Bangladesh (5), Brazil (5), Indonesia (5), Nigeria (5), Ghana (3), Ethiopia (4) and

Tanzania (2) and ten studies are conducted in more than one country. Noteworthy is that India, Brazil and Indonesia combined account for over 75% of newly diagnosed leprosy cases globally.



3.6 COMPLETED PROJECTS

The following projects have been successfully completed in 2024:

- [703.15.41](#) Helminth Influences in Leprosy: Indicators, Treatment, Reactions and Clinical Outcome
- [706.18.39](#) Functional analysis of candidate variants in the early-onset leprosy phenotype using a novel cellular model
- [707.19.60](#) Collaboration with traditional healers to reduce the delay of leprosy diagnosis and improve detection of hidden leprosy patients in Sierra Leone through establishment of a referral system
- [708.20.15](#) Improving mental health and quality of life of persons affected by leprosy or Buruli ulcer in Southern Nigeria
- [FP21\17](#) Assessing Electronic Data Collection Tools, Pathways and HMIS Integration for Leprosy and LF MMDP Data to Improve Service Delivery
- [FP21\8](#) The Use of Molecular Methods in Subclinical Murine Models of Leprosy to Examine the Efficacy of Proposed Post-Exposure Prophylaxis (PEP) Regimens
- [FP21\26](#) Exploring strategies and identifying effective mechanisms to mobilise persons disabled as a result of Neglected Tropical Diseases (NTD) to influence policy and programs to ensure person centered approach for affected persons in Cote d'Ivoire
- [FP22\8](#) Endgame strategy for leprosy in the Maldives: optimal targeting of post-exposure prophylaxis to interrupt transmission
- [FP23\13](#) Leprosy incidence, clustering and risk factors: Evidence from 5-year follow-up trial Maltalep and Ideal study in Bangladesh
- [PEP4LEP](#) Chemoprophylaxis for leprosy: comparing the effectiveness and feasibility of a skin camp intervention to a health centre based intervention. An implementation trial in Mozambique, Ethiopia and Tanzania
- [FP22\15](#) Participatory development of audio-delivered interventions and written material and assessment of their impact on the perception and knowledge of and attitudes towards leprosy: a cluster randomised trial in Nigeria

LRI values high scientific standards and capacity strengthening, though we recognise that these do not always go hand in hand. At the same time, we remain accountable to our funding partners. Our grant award letters clearly stipulate the circumstances under which we may terminate a grant, which we have done this year for two projects. This was not a decision we took lightly, and we acknowledge the implications it has had for the research

teams involved and the participants of the studies. However, the decision was made after repeated concerns were raised by the Scientific Review Committee regarding the lack of communication and progress in these projects, despite multiple opportunities given to improve performance.

4 STRENGTHENING RESEARCH CAPACITY

An important objective of LRI is to strengthen capacity of researchers and organisations, with a focus on those based in leprosy-endemic countries and early career researchers. Several activities in 2024 were organised with the aim to contribute to expanding research knowledge, skills and experience.

4.1 LRI SPRING MEETING – IN-PERSON EVENT


The ninth annual LRI Spring Meeting was held on 17-19 April 2024 in Eindhoven, the Netherlands. The event brought together nearly 100 attendees from 25 countries, including LRI-funded researchers, LRI committee members, partners of LRI, representatives of collaborating organisations, and other attendees with a particular interest in leprosy research.

During the Spring Meeting, the progress and results from ongoing LRI-funded research projects are presented and discussed. The event is also a platform for shared learning and networking.

In total, 39 progress presentations were given on ongoing LRI-funded projects covering all five LRI research priorities, including from the two new research capacity strengthening grant awardees. Additionally, Dr Subbanna Jonnalagada (WHO Global Leprosy Programme) and Dr Wim van Brakel (NLR) gave keynote presentations on the global leprosy situation and progress towards interruption of transmission and elimination.

Plenary presentations were also given by several LRI collaborating organisations on their invaluable work towards our shared aim of beating leprosy and NTDs. We are grateful to the WHO Skin-NTD Programme representatives, Anesvad Foundation, EDCTP, and Infolep and InfoNTD for their presentations and valuable contributions to the Spring Meeting, which enriched the participants and fostered meaningful discussions. On Friday morning, participants attended break-out sessions on topics of their preference including research impact, endpoints for clinical trials, and stakeholders speed dating, all sparking lively discussions, innovative ideas and new connections.

Dr Suzan Trienekens, Coordinator of LRI shares: *“It is an absolute honour to organise this event for the LRI community. Although we are diverse across disciplines and countries, expertise and experience, we share the strong commitment to eliminate leprosy and NTDs through impactful research. You can really feel the buzz of sharing of insights, the forming of new connections and the strengthening of collaborations at the LRI Spring Meeting.”*



4.2 ONLINE HIGHLIGHTS OF LRI SPRING MEETING EVENT

In 2023, LRI hosted the online 'Highlights of LRI Spring Meeting' event for the first time, and after its success in reaching global audiences including many who had not attended an LRI Spring Meeting before, the webinar returned in 2024. The online event, held on 30 May, included the showcasing of selected project progress presentations from the in-person meeting, and a special session on LRI research impact.

The event was open to everyone with an interest in leprosy research and participation was free-of-charge. This virtual gathering aimed to provide an opportunity for global participation. Over 90 participants joined from all around the world, highly valuing the opportunity to learn about a range of leprosy research topics and LRI's projects, as indicated by their survey feedback. One attendee stated *"I have a long list of take-home messages but several findings from LRI funded researches are certainly helpful in meeting the set target for zero leprosy."*

4.3 RESEARCH CAPACITY STRENGTHENING GRANT

The Research capacity strengthening grant was launched for the first time in December 2022. This grant specifically focuses on capacity strengthening of early career leprosy researchers across the five LRI priority areas.

At the end of the first grant cycle, two early-career researchers were awarded the Research Capacity Strengthening Grant in June 2023 and began their projects. Since then, they have been actively working on their research and presented their projects at the LRI Spring Meeting 2024. Following this, they also participated in the scientific writing workshop, both these activities further enhanced their skills and confidence.

In 2024, we prepared for the next round of this grant. The new call was launched in December 2024 and received significant interest, with 53 applications submitted by early-career researchers. By the end of June 2025, after completing the review process, the next cohort of Research capacity strengthening grant recipients will be awarded.

We are excited about this next phase and remain committed to strengthening research capacity in endemic countries.



4.2 WORKSHOP ON SCIENTIFIC WRITING

In previous years, the LRI has organised four operational research workshops aiming to strengthen the capacity of LRI-funded researchers. In 2024, LRI hosted a workshop focusing on scientific writing. This topic was recommended by the Steering Committee as well as through the impact assessment and aims to strengthen capacity on writing a scientific paper for publication in a peer-reviewed journal.

For the first time, we used a blended learning approach for an LRI workshop, offering online learning followed by face-to-face training and guidance. LRI collaborated with the ILEP supported Lift Leprosy Learning project, NLR, KNCVTB+ and Health[e]Foundation to develop an e-course on scientific writing, which was hosted on the e-learning platform of InfoNTD.

These modules gave participants from selected LRI-funded projects in advanced stages of their research the context in preparation of the in-person 4-day workshop which was hosted following the LRI Spring Meeting (April 21-24). There, they had the

opportunity to progress on their paper under the guidance of experienced mentors.

The feedback from participants was very positive, as reflected in the following survey response: *"The workshop was well organised, the mentors are knowledgeable and very supportive. The workshop provided opportunity to spend dedicated time on making considerable progress on my manuscript within a short time, which may not have been possible if I were to combine it with official duties."*

We hope this initiative will boost sharing of research findings and build towards a more sustainable training environment for early career researchers of LRI-funded projects.



5 FACILITATING TRANSLATION OF RESEARCH RESULTS INTO POLICY AND PRACTICE

LRI considers it important that research results are applicable to interrupt transmission, improve leprosy services and/or contribute to the wellbeing of persons affected by leprosy. In order to achieve such impact we encourage researchers to involve stakeholders in the research development and implementation process and in the dissemination of findings to optimise uptake.

5.1 IMPACT ASSESSMENT

In 2023, a research impact assessment was undertaken to better understand projects' impact and identify facilitators and barriers towards stronger impact.

The assessment yielded several valuable recommendations for enhancing monitoring, and sharing the impact of LRI-funded projects in the coming years, which will be taken forward. These included developing a guidance for researchers,

revising how we capture impact during the project and after completion, and new ways to regularly share research findings with stakeholders.

In 2024, we have revised the progress report template to better capture impact beyond the scientific sector (e.g. research-related, policy-related, health-related, and societal-related). The study's findings were presented at the in-person LRI Spring Meeting and as part of the online Highlights

of LRI Spring Meeting. At the LRI Spring Meeting in Eindhoven, break-out sessions on 'Research impact' were facilitated aiming to get further feedback from researchers of ongoing projects and other stakeholders. The aim of this session was to exchange and discuss information on LRI research impact, which will be used as input to contribute to improved LRI processes and resources for supporting grantees to generate impact through their research projects, monitor, and disseminate.

We are looking forward to the continuous work on improving our processes to better support researchers to work on impactful projects.



5.2 ADVANCING LEPROSY AND NTD IMPACT THROUGH COLLABORATION

Collaboration remained at the heart of our work, and we were actively involved in and supported important events for the leprosy and Neglected Tropical Diseases (NTDs) landscape.

In May 2024, over 50 experts from 25 countries gathered in Bergen, Norway, for the **Zero Transmission Symposium** to discuss strategies for achieving the interruption of transmission of *Mycobacterium leprae*. The symposium reviewed recent developments in understanding transmission and explored the knowledge, tools, and interventions still needed to reach the joint goal of zero transmission.

LRI was honoured to support the Global Partnership for Zero Leprosy (GPZL) in bringing together researchers from various disciplines, WHO representatives, control programme managers, individuals with lived experience, medical staff, and funders for this important event, hosted by the University of Bergen. We look forward to the outcomes of the symposium, including a forthcoming publication.



The **15th Annual Neglected Tropical Disease NGO Network (NNN) Conference**, hosted in Malaysia, brought together NTD practitioners, government leaders, persons affected, researchers, policymakers, and other stakeholders from over 50 countries to collaborate towards sustainable progress on our shared goal to combat NTDs, including leprosy. Dr Suzan Trienekens, LRI Coordinator, shared insights on the challenges and opportunities for the meaningful involvement of affected individuals in leprosy research and how funders like LRI can contribute. The discussions underscored the importance of involving affected individuals from multiple perspectives, sparking valuable conversations and input.



5.3 COMMUNICATIONS

Project publications were reported by the research groups through progress reports and email, and subsequently added to the LRI website.

In 2024, the LRI website received more than 6,300 visitors. Several newsletters were sent throughout the year, keeping our 1,400+ contact subscribers informed about the latest LRI news and updates.

The LRI Communications Committee (COCO), which brings together communication representatives from our Full Partner organizations, convened quarterly to discuss LRI communications matters. With their guidance and expertise, we are

strengthening our communications and keeping our audiences informed about research findings, achievements, opportunities, and new developments.

The [LRI LinkedIn channel](#) has been an essential platform for keeping our audience up-to-date with LRI developments and activities, with a weekly posting schedule. Through this platform, we disseminate updates and engage a network of individuals committed to eliminating leprosy. Since the launch of the channel, it has gained over 850 followers.

6 FUTURE PERSPECTIVES

In December 2024, funding allocations for successful proposals were finalised, new calls for proposals were launched, and the annual plan for 2025 was agreed upon. In 2025, we are excited to drive innovation by selecting impactful new research proposals and supporting ongoing projects.

The tenth edition of the LRI Spring Meeting will be held online in April 2025, bringing together researchers from funded projects, LRI committee members, and other stakeholders. The online format will enable global participation, fostering a broader exchange of experiences and ideas. Additionally, we look forward to connecting with many of you at the International Leprosy Congress in Indonesia.

In 2025, the second five-year audit will be completed, focusing on the evaluation of capacity-strengthening activities and partnerships. Based on the recommendations from the audit, we aim to enhance the quality, efficiency, and sustainability of the Initiative.

We also aim to further increase the visibility and reach of LRI activities by strengthening internal and external communication and engagement with researchers, partners, and other stakeholders. We will follow up on recommendations from the impact assessment to better support, monitor, and share the impact of funded projects.

Lastly, we look forward to continuing our collaboration with the Global Partnership for Zero Leprosy's research pillar to implement the global research agenda and advance our shared goal of promoting and facilitating high-quality leprosy research.

7 OUR PARTNERS IN 2024

In 2024, the Leprosy Research Initiative comprised the following Partners:



We are grateful to the additional financial support that is provided to the Leprosy Research Initiative by the following organisations:



Interested to become a Partner of LRI and contribute to boosting scientific research in leprosy?
Contact us at info@leprosyresearch.org

8 OUR TEAM IN 2024

8.1 EXECUTIVES GROUP

Ms Linda Hummel	CEO, NLR (Chair)
Mr Joachim Beringer	CEO, GLRA
Mr Brent Morgan	Director, TLMI
Mr Bill Simmons	President/CEO, ALM
Mr Iñigo Lasa	Director General, Anesvad Foundation

8.2 STEERING COMMITTEE

Dr David Scollard (until November)	Former Director of the US National Hansen's Disease Programs (Chair)
Prof. Jan Hendrik Richardus (from November)	Emeritus Professor of Infectious Diseases and Public Health (retired), Erasmus MC, University Medical Center Rotterdam (Chair)
Dr Wim H. van Brakel	Medical Director, NLR
Dr Christa Kasang	Research Coordinator, GLRA
Ms Jannine Ebenso	Head of Quality Assurance, TLMI
Dr Sunil Anand	Regional Director for Asia, ALM
Dr Lucrecia Acosta Soto	Associate Professor, University of Michael Hernandez de Elche
Ms Arantzazu Quintana / Ms Anna Giné	International Cooperation / Research, Anesvad Foundation
Dr Peter Steinmann	Public Health Specialist and Epidemiologist, Swiss Tropical and Public Health Institute

8.3 SCIENTIFIC REVIEW COMMITTEE

Dr Richard W. Truman (Chair)	Former Chief of the Laboratory Research Branch of the National Hansen's Disease Program / Principal Investigator of the Leprosy Research Support program of the National Institutes of Allergy and Infectious Disease, USA
Dr Jos H.M. Dekker (until October)	Rehabilitation Physician (retired), Heliomare Rehabilitation Centre at Red Cross Hospital, the Netherlands
Prof. Dr Françoise Portael	Professor Emeritus, Institute of Tropical Medicine Antwerp, Belgium
Prof. Dr Patricia D. Deps	Full Professor and Head of the Department of Social Medicine, Postgraduate Programme in Infectious Diseases, Federal University of Espirito Santo, Brazil
Prof. Dr Paul Fine	Professor Emeritus of Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, United Kingdom
Dr Zoica Bakirtzief	Adjunct Associate Professor (External Professor), Psychology Department, Federal University of Santa Maria, Brazil
Dr Ad P. Koets	Senior Scientist and Head of the National Reference Laboratory for Mycobacterial Infections and Tuberculosis at Wageningen Bioveterinary Research (WBVR), the Netherlands
Dr Cassandra White	Associate Professor of Anthropology, Department of Anthropology, Georgia State University
Dr Kathryn M. Dupnik (from October)	Assistant Professor of Medicine in Infectious Diseases and Microbiology and Immunology at Weill Cornell Medicine, as well as faculty in the Center for Global Health, USA.
Dr Frederik J. Slim (from October)	Rehabilitation Specialist and Staff Member, Department of Rehabilitation Medicine Rivierenland Hospital, Tiel, the Netherlands.

8.4 LRI COMMUNICATIONS COMMITTEE (COCO)

Mr Stephen Labib	International Communication Advisor, NLR
Mr Guillermo Maceiras	Strategic communication, Anesvad Foundation
Ms Sarah Hesshaus	Vice President of Business Process & Communications, ALM
Ms Jessica Mussro	Communications Manager, ALM
Mr Tim Burton	Global Communications Lead, TLMi
Mr Subhojit Goswami	Senior Program Manager - Advocacy & Communications, TLM India
Ms Johanna Schultheiß	Press and Public Relations Officer, GLRA
Ms Larissa Brodziak	Online Fundraiser, GLRA

8.5 LRI SECRETARIAT

Dr Suzan Trienekens	Coordinator
Ms Nicole Dinnissen	Programme Officer
Ms Chrysa Menexi	Support Officer

9 REVIEWER ACKNOWLEDGEMENTS

We would like to thank all our external reviewers who dedicated their time to the peer review of the full proposals of the Regular and RESILIENTD grants in 2024:

ALEXANDRA AUBRY
ALFRED KWESI MANYEH
ANNE SCHOENMAKERS
APARNA SRINKANTAN
BENEDICT OKOE QUAO
BOUKE DE JONG
BRONWEN GILLESPIE
CARMEN LOGIE
CAROLIN GUNESCH
CARRIE BARRETT
CHARLES PHAFF
CHIRANJIBI SHARMA
CHRISTINE FENENGA
EMMANUELLE CAMBAU
ENNY RACHMANI
ENTE ROOD
ERIK POST
ERIK SLIM
FUREN ZHANG
GIDADO MUSTAPHA
GUNNAR AKSEL BJUNE
ISABELA DE CAUX BUENO
ISRAEL CRUZ MATA
JAMES GILCHRIST
JULIAN EATON
KATHY FIEKERT
KENNEDY ADDO KWASI

KESHAR MOHANTY
MANFRED EGBE
MANNAM EBENEZER
MARIA PENA
MARLIES VISSER
MATILDA ABERESE-AKO
MAYA RONSE
MIKAELA COLEMAN
NGOZI EKEKE
PAULA BRANDÃO
PETER NUGUS
RAMANUJ LAHIRI
ROXANE SCHAUB
SARJU SING RAI
SELVASEKAR ABRAHAM
SERGI ALONSO
SETH CHRISTOPHER YAW APPIAH
SHEIKH ALIF
SUJAI SUNEETHA
SUNDEEP CHAITANYA VEDITHI
TAIWO JAMES OBINDO
TANJA BARTH-JAEGGI
TJIP VAN DER WERF
TOM GILLIS
WARWICK BRITTON
WIM BRANDSMA

10 FINANCIAL NARRATIVE

Summary Budget LRI 2025

	Budget 2025	Actuals 2024
Income:		
Income from contributors	870.000	1.099.243
Other income	641.000	292.440
Income in return of goods and services	79.000	86.877
Sum of income	1.590.000	1.478.560
Expenses:		
Project costs	1.570.000	1.199.654
Running costs	308.000	292.648
Sum of expenses	1.878.000	1.492.302
Result	-288.000	-13.742

Financial results 2024

In 2024 LRI received a total contribution from partners of €1,099,243 and in addition to this an amount of €292,440 was received from co-funding partners towards specific research projects and running costs. The freely available funds consist of cash held in the bank account and amount to €1,998,288 as per 31 December 2024.

The total expenses arrived at €1,492,302. The deficit of 2024 amounting to €13,742 is withdrawn from the earmarked reserves of LRI. This decreased the total earmarked reserves from €1,341,382 to €1,327,640. The earmarked reserves are formed in accordance with LRI policy, please refer to the section notes accompanying the annual accounts for 2024 for further clarification.

Outlook 2025

LRI will receive a contribution of €870,000 from partners, an amount of €641,000 for co-financed projects and an amount of €79,000 in return of goods and services. Looking forward, we expect the expenditures to increase to €1,570,000 due to an expected increase in project activities.

11 ANNUAL ACCOUNTS

Amsterdam, the Netherlands

Date: 25 June 2025

CONTENTS

I. Balance sheet as at 31 December 2024	20
II. Statement of Income and Expenses 2024	21
III a. Notes accompanying the Annual Accounts 2024	22
III b. Notes to Balance sheet 2024	24
III c. Notes to the Income and Expenditure 2024	26
IV Independent auditor's report	28
V Annexes.....	29
annex V.1 Overview of research projects	30
annex V.2 Budget LRI 2025	31
annex V.3 Multi Annual Budget LRI 2025-2027	32
annex V.4 Board and Executives Group of LRI.....	33

I. BALANCE SHEET AS AT 31 DECEMBER 2024

amounts in €

Notes	31 December 2024	31 December 2023
ASSETS		
2. Current assets		
Accounts receivables	-	125.641
Balances and accounts from NLR	40.434	960.607
Other receivables and amounts paid in advance	3.736	19.481
Cash and cash equivalents	<u>1.998.288</u>	<u>587.291</u>
Total assets	<u>2.042.458</u>	<u>1.693.020</u>
LIABILITIES		
3. Reserves		
Earmarked reserves	<u>1.327.640</u>	<u>1.341.382</u>
	1.327.640	1.341.382
4. Short-term liabilities		
Anesvad Foundation	400.000	-
Other payables and amounts received in advance	<u>314.818</u>	<u>351.638</u>
	714.818	351.638
Total liabilities	<u>2.042.458</u>	<u>1.693.020</u>

II. STATEMENT OF INCOME AND EXPENSES 2024

amounts in €

Notes	Actuals 2024	Budget 2024	Actuals 2023
5. INCOME			
Income from contributors	1.099.243	1.100.100	1.130.988
Other income	292.440	573.631	263.880
Income in return of goods and services	86.877	68.553	37.011
Total income	1.478.560	1.742.284	1.431.879
6. EXPENSES			
Project costs	1.199.654	1.987.798	1.234.262
Staff costs, housing and office costs	257.848	247.250	226.283
Other operating expenses	34.800	50.592	25.853
Total expenses	1.492.302	2.285.640	1.486.398
Result of income and expenses	-13.742	-543.356	-54.519

III A. NOTES ACCOMPANYING THE ANNUAL ACCOUNTS 2024

General and accounting policies

These are the annual accounts of 2024 of the Leprosy Research Initiative (LRI). The year 2024 started on January 1st and ended December 31st. LRI has been registered since June 1st 2015 as a foundation under Dutch law. LRI is registered at the Chamber of Commerce no. 63431874.

General note on the accounting policies

The annual accounts have been prepared in accordance with Guideline C for small non-profit organisations (Dutch: Richtlijn C1 Kleine organisaties zonder winststreven) as published by the Dutch Accounting Standards Board (Raad voor de Jaarverslaggeving) and revised in 2023.

Activities

The LRI is a leprosy research funding and capacity strengthening organisation. Partners of the LRI contribute to a joint fund which is managed by the LRI and reserved for research that is exclusively or strongly related to leprosy. An efficient, transparent and scientifically sound and rigorous selection process assures a transparent selection of research proposals as well as a scientifically high-quality monitoring mechanism of research projects. A comprehensive explanation of our mission and goals and a detailed account of the content of our work can be found in our annual report.

The LRI work proceedings and work activities.

The LRI fully delegated its work proceedings and activities to NLR. The Supervisory Board of NLR supervises the proceedings and activities as reported by the NLR Director.

Registered address

The registered and actual address of the LRI is Wibautstraat 137k, 1097 DN in Amsterdam, the Netherlands.

Accounting period

The annual accounts have been drawn up for an accounting period of one year. The financial year is equal to the calendar year. The annual accounts

have been prepared on a historical cost basis of accounting.

Accounting policies for the valuation of assets and liabilities and the determination of the result

All amounts in the annual accounts are in € or a multiple of €1,000 or rounded to the nearest amount in €. The amounts are compared to the part for research activities and objectives from the formal LRI budget for 2024 (approved by the Supervisory Board in December 2023).

The annual accounts have been prepared in accordance with the principle of continuity.

Income from funding and the allocation of funds

Each LRI full partner has committed an annual contribution to the LRI joint fund for research projects and contributes an equal share to LRI running costs. Associate partners and co-financiers contribute to specific projects and/or to the running costs. The income from full partners, associate partners and co-financiers are recognised in the year to which the item of income relates and are allocated to the year in question on an actual cost basis. The income is shown gross, before any deduction of associated costs, unless otherwise stated. Necessary costs to realise certain benefits, are presented in the statement of income and expenses as expense.

Grant commitments

The grant commitments are recognised as conditional commitments. The LRI receives from the grantees two progress reports annually, including scientific progress regarding the research project and financial statements: a semi-annual report and an annual report. The semi-annual report must be submitted each year on September 1st. The deadline for submission of the annual report is March 1st.

The amounts that are expected to be settled in future years are accounted for, insofar as expenditures are appropriate within the condition,

are included as short-term liabilities. The LRI does not hold any long-term liabilities.

Accounts receivable

Receivables are initially valued at the fair value of the consideration to be received, including transaction costs if material.

Cash and cash equivalents

Cash and cash equivalents include cash and bank balances that represent the balance of the bank account held for the Secretariat of the LRI, in the Netherlands and are immediately accessible. The LRI does not have any borrowings or loans. The LRI does not invest, nor does it make use of any financial instruments.

General note on the balance sheet and statement of income and expenses

In general, assets and liabilities are stated at the amounts at which they were acquired or incurred, or at current value. If not specifically stated otherwise, they are recognised at the amounts at which they were acquired or incurred. The balance sheet and statement of income and expenses include references to the notes. Notes to the line items of the balance sheet and the statement of income and expenses have been numbered in the financial statements.

Foreign currency

The annual accounts are presented in €. Transactions in foreign currency are converted to € at the exchange rate of the transaction date.

Reserves

The LRI ensures that contributions are used for the intended cause. If more funds are allocated to a specific research project than the reported

expenditure in that particular year for that project, the LRI will allocate the surplus amount to the same project in the remaining grant period. If, upon completion, the actual expenditures of a specific project are lower than the grant awarded, the remaining budget will be deposited in the joint fund. The (earmarked) reserves are the result of income and expenses and are held in accordance with budgets for grant awards and for the running costs of the LRI for future years.

Reserves and investments

The result of 2024 is withdrawn from the earmarked reserves. The earmarked reserves are used for active and new grant awards as well as running costs to ensure the sustainability of the LRI with a horizon of three years. The LRI holds no investments.

Management of the LRI and remuneration of Supervisory Board and Executives Group

The LRI is managed by the Director of NLR, implementing the decisions of the LRI Executives Group and supervised by the Supervisory Board of NLR. No remuneration was paid to the Supervisory Board members and Director of NLR, and no loans, advances or guarantees were given.

Events after the reporting period

In these accounts no significant events after the reporting period occurred which should be included.

Publication

This report is available on www.leprosyresearch.org. The 2024 annual report and the annual accounts are available in a digital format primarily for environmental reasons. A (free of charge) printed copy can be obtained on request.

III B. NOTES TO BALANCE SHEET 2024

In the notes to the balance sheet variances between 2023 and 2024 are elaborated upon further.

1. Tangible fixed assets

Tangible fixed assets are used for the main activities and entirely held for operational management. The LRI holds no tangible fixed assets and therefore this is not valued in 2023 and 2024.

2. Current assets

This item includes all receivables which are due within one year, amounts paid in advance and cash and cash equivalents.

	31 December 2024	31 December 2023
	in €	in €
Accounts receivables	-	125.641
Balances and accounts from NLR	40.434	960.607
Other receivables and amounts paid in advance	3.736	19.481
Cash and cash equivalents	1.998.288	587.291
	2.042.458	1.693.020

The item Balances and accounts from NLR relates to the receivable funds from NLR. In previous years an amount of €1 million has been temporarily deposited in the account of NLR as part of LRI's cash management. In December 2024, this amount was returned to a savings account of LRI.

The Cash and cash equivalents balance increased by €1.4 million during the financial year. This consists of €1 million in the bank's savings account (see note above) and an amount received in advance from Anesvad of €0.4 million in the bank's current account (see item 4 of the balance sheet).

The balance of cash and cash equivalents are available immediately.

3. Reserves

The LRI ensures that contributions are used for the intended cause. If more funds are allocated to a specific research project than the reported expenditure in that particular year for that project, the LRI will allocate the surplus amount to the same project in the remaining grant period. If, upon completion, the actual expenditures of a specific project are lower than the grant award, the remaining budget will be deposited in the joint fund. The (earmarked) reserves are the result of income and expenses and are held in accordance with budgets for grant awards and for the running costs of the LRI for future years.

The LRI's reserves are as follows:

	31 December 2024	31 December 2023
	in €	in €
Earmarked reserves	1.327.640	1.341.382

General notes on the reserves

For the budget of 2024, a deficit of €543,000 was accounted. Several of the research projects have experienced delay in progress. Reasons include delays in ethical approvals, project management issues, site changes, personnel turnover, enrolment challenges, political instability, and natural disasters. Following review by the Scientific Review Committee, the LRI Executives Group has accepted requests from projects for no-cost extensions to continue activities related to the grant award.

The negative result of 2024 arrived at €13,742 and is withdrawn from the earmarked reserves of the LRI.

While partners contribute to the joint fund, associate partners and co-financers contribute to specific projects. Some of the funds received in 2024 for specific projects remained unspent. These have been re-allocated to the 2025 budget. The LRI holds no continuity reserve.

	Earmarked reserves in €
Balance as per 1 January 2024	1.341.382
- Movements	-
- Withdrawals and additions	-13.742
Balance as per 31 December 2024	1.327.640

4. Short term liabilities

All current liabilities fall due in maximum four years from date of signature. The fair value of the current liabilities approximates the book value due to its short-term character.

	31 December 2024 in €	31 December 2023 in €
Anesvad Foundation	400.000	-
Other payables and amounts received in advance	314.818	351.638
	714.818	351.638

In collaboration with Anesvad Foundation, a new call for proposals was launched in December 2023 for projects commencing in 2025: the RESILIENTD grant, which has a special focus on the social determinants of skin NTDs in Sub-Saharan Africa. The RESILIENTD Grant is facilitated by the LRI Secretariat, supported by LRI structures, and funded by Anesvad Foundation. Anesvad Foundation provides LRI with annual funding for this grant over 4 budget rounds, with a maximum of €800,000 per round. As per the agreement, 50% of Anesvad Foundation's allocated project funding for projects starting in 2025 (€0.4 million) was received in advance by LRI.

Accounts payable mainly consist of amounts due for audit and project costs that have not yet been invoiced in 2024. The amounts received in advance (€277,789) are also included under this item, representing unspent funds from contributors towards research projects.

Commitments not included in the balance sheet

As at 31 December 2024, LRI's commitment for running research projects amounted to €1,200,744.

Events after balance sheet date

No events have occurred between the balance sheet date and the date on which the Supervisory Board adopted the annual accounts, which would affect the 2024 annual accounts or the condition of LRI at the end of the financial year or thereafter.

III C. NOTES TO THE INCOME AND EXPENDITURE 2024

5. Income

Each LRI full partner has committed an annual contribution of a minimum of €100,000 to the joint LRI research fund and contributes an equal share to the LRI running costs. In 2024 the full partners were: American Leprosy Missions (ALM), German Leprosy and Tuberculosis Relief Association (GLRA/DAHW), The Leprosy Mission (TLM) International, Anesvad Foundation, and NLR. Associate partners, in 2024 these were Damien Foundation and Effect Hope, contributed a chosen contribution less than €100,000 to the joint fund and did not contribute to the running costs. The breakdown of the total income is as follows:

	Actuals 2024	Budget 2024	Actuals 2023
	in €	in €	in €
Income from contributors			
ALM	143.700	143.700	173.970
GLRA/DAHW	193.700	193.700	194.000
TLM International	143.700	143.700	144.000
Anesvad Foundation	200.000	200.000	200.000
NLR	350.000	350.000	350.000
Damien Foundation	35.000	35.000	35.000
Effect Hope	33.143	34.000	34.018
Other income			
Turing Foundation	209.152	457.085	208.711
Other amounts from partners	73.288	105.546	43.391
Other amounts	10.000	11.000	11.778
Income in return of goods and services			
Others	86.877	68.553	37.011
	1.478.560	1.742.284	1.431.879

The total amount of income available for allocation in line with the objectives for 2024 arrived at €1,478,560.

The actuals of the total income in 2024 was 15% lower than budgeted.

The earmarked contribution from Turing Foundation amounts to €209,152. Additionally, Turing Foundation contributed €10,000 towards running costs. For 2024 we received an earmarked contribution of €73,288 from St Francis Leprosy Guild. The amount of €86,877 under the item Income and return of goods and services related to the contribution of the Anesvad Foundation and the contribution of the Global Partnership for Zero Leprosy (GPZL) towards the running costs of LRI (mainly salary costs) and the LRI Spring Meeting registrations.

6. Expenses

Research

The expenses mainly consisted of funding of research projects costs in line with the active grant awards. A total of 45 research projects were funded in 2024 (see annex 1 for expense details by projects).

	Actuals 2024	Budget 2024	Actuals 2023
	in €	in €	in €
Research			
Research projects costs	1.040.350	1.782.798	1.145.144
Other projects costs	159.304	205.000	89.118
	1.199.654	1.987.798	1.234.262

The LRI spent a total of €1,199,654 on project funding in 2024. The actual project costs were 60% of the budgeted project costs. The difference is mainly due to the premature termination of funding for two large research projects. Additionally, due to requested and approved no-cost extensions, instalments were transferred later than originally planned or postponed to 2025. Furthermore, for some research projects that ended in 2024, actual expenses were lower than anticipated, resulting in a lower final payment. Lastly, several newly granted research projects began activities in the second half of 2024, while the budget had been estimated for the full calendar year.

Running costs

The LRI running costs consist of staff costs for the LRI Secretariat staff, housing expenses and other operating expenses that cannot be directly allocated to the projects. The actuals of staff costs were 5% higher than budgeted and the housing and office expenses of 2024 were in accordance with the budget, other operating expenses were almost 31% below budget.

	Actuals 2024	Budget 2024	Actuals 2023
	in €	in €	in €
Running costs			
Staff costs	225.598	215.000	197.283
Housing and office costs	32.250	32.250	29.000
Other operating costs	34.800	50.592	25.853
	292.648	297.842	252.136

	Actuals 2024	Budget 2024	Actuals 2023
	in €	in €	in €
Staff expenses			
Wages and salaries	175.163	167.000	149.604
Social security costs	29.150	28.000	24.345
Pension contributions	19.886	19.000	16.471
Other personnel costs	1.399	1.000	6.863
	225.598	215.000	197.283

In 2024 on average 2.8 FTEs (2023: 2.6 FTEs) were employed in the Secretariat of the LRI in Amsterdam. The LRI had no staff employed abroad during 2024.

The LRI has no staff members on its payroll; all staff is employed by NLR and the expenditure is charged to the LRI. For the LRI Secretariat staff, the NLR standard terms, benefits, and conditions of employment apply. The total staff costs of the LRI for 2024 amount to €225,598 and consist of wages and salaries, pension costs (insured with Pensioenfonds Zorg en Welzijn), social security charges and other personnel costs.

IV INDEPENDENT AUDITOR'S REPORT

INDEPENDENT AUDITOR'S REPORT

To: the supervisory board and the management of
Stichting Leprosy Research Initiative.

A. Report on the audit of the financial statements 2024 included in the annual report.

Our opinion

We have audited the financial statements 2024 of Stichting Leprosy Research Initiative based in Amsterdam, the Netherlands.

In our opinion, the accompanying financial statements give a true and fair view of the financial position of Stichting Leprosy Research Initiative at 31 December 2024 and of its result for 2024 in accordance with the 'RJ-Richtlijn C1 Kleine organisaties zonder winststreven' (Guideline for annual reporting C1 'Small not-for-profit organisations') of the Dutch Accounting Standards Board).

The financial statements comprise:

1. the balance sheet as at 31 December 2024;
2. the statement of income and expenditure for 2024; and
3. the notes comprising of a summary of the accounting policies and other explanatory information.

Basis for our opinion

We conducted our audit in accordance with Dutch law, including the Dutch Standards on Auditing. Our responsibilities under those standards are further described in the 'Our responsibilities for the audit of the financial statements' section of our report.

We are independent of Stichting Leprosy Research Initiative in accordance with the Verordening inzake de onafhankelijkheid van accountants bij assurance-opdrachten (ViO, Code of Ethics for Professional Accountants, a regulation with respect to independence) and other relevant independence regulations in the Netherlands. Furthermore we have complied with the Verordening gedrags- en beroepsregels accountants (VGBA, Dutch Code of Ethics).

We believe the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Wamberg Offices
Wamberg 37
1083 CW Amsterdam
Postbus 53028
1007 RA Amsterdam
Telefoon 020 571 23 45

E-mail info@dubois.nl
www.dubois.nl
KvK nummer 34374865



B. Report on the other information included in the annual report.

The annual report contains other information, in addition to the financial statements and our auditor's report thereon.

The other information consists of:

- the Management Board's report;
- Annex V-1: Overview of projects ongoing in 2024;
- Annex V-2: Budget LRI 2025;
- Annex V-3: Multi Annual Budget LRI 2025-2027;
- Annex V-4: Board and Executives Group of LRI.

Based on the following procedures performed, we conclude that the other information is consistent with the financial statements and does not contain material misstatements.

We have read the other information. Based on our knowledge and understanding obtained through our audit of the financial statements or otherwise, we have considered whether the other information contains material misstatements.

By performing these procedures, we comply with the requirements of the Dutch Standard 720. The scope of the procedures performed is substantially less than the scope of those performed in our audit of the financial statements.

Management is responsible for the preparation of the other information, including the Management Board's report in accordance with Guideline for annual reporting 'RJ-Richtlijn C1 Kleine organisaties zonder winststreven' (Guideline for annual reporting C1 'Small not-for-profit organisations').

C. Description of responsibilities regarding the financial statements

Responsibilities of the supervisory board and the management for the financial statements.

Management is responsible for the preparation and fair presentation of the financial statements in accordance with the Guideline for annual reporting 'RJ-Richtlijn C1 Kleine organisaties zonder winststreven' (Guideline for annual reporting C1 'Small not-for-profit organisations'). Furthermore, management is responsible for such internal control as management determines is necessary to enable the preparation of the financial statements that are free from material misstatement, whether due to fraud or error.

As part of the preparation of the financial statements, management is responsible for assessing the foundation's ability to continue as a going concern. Based on the financial reporting framework mentioned, management should prepare the financial statements using the going concern basis of accounting, unless management either intends to dissolve the foundation or to cease operations, or has no realistic alternative but to do so.

Management should disclose events and circumstances that may cast significant doubt on the foundation's ability to continue as a going concern in the financial statements.

The supervisory board is responsible for overseeing the organisation's financial reporting process.

Our responsibilities for the audit of the financial statements

Our objective is to plan and perform the audit engagement in a manner that allows us to obtain sufficient and appropriate audit evidence for our opinion.

Our audit has been performed with a high, but not absolute, level of assurance, which means we may not detect all material errors and fraud during our audit.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. The materiality affects the nature, timing and extent of our audit procedures and the evaluation of the effect of identified misstatements on our opinion.

We have exercised professional judgement and have maintained professional skepticism throughout the audit, in accordance with Dutch Standards on Auditing, ethical requirements and independence requirements.

Our audit included among others:

- identifying and assessing the risks of material misstatement of the financial statements, whether due to fraud or error, designing and performing audit procedures responsive to those risks, and obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
- obtaining an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control;
- evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management;
- concluding on the appropriateness of management's use of the going concern basis of accounting, and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the foundation's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause a foundation to cease to continue as a going concern.
- evaluating the overall presentation, structure and content of the financial statements, including the disclosures; and
- evaluating whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.



We communicate with the supervisory board and the management regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant findings in internal control that we identify during our audit.

Amsterdam, 26 June 2025

Dubois & Co. Registeraccountants

Signed on original:
A.P. Buteijn RA and A. Koek RA

V ANNEXES

annex V-1 Overview of projects ongoing in 2024

Projectno.	Project title	Actuals 2024	Budget 2024
703.15.41	TLM Nepal/Helminth influences in leprosy	20.000	20.000
704.16.71	ENLIST MTX - two randomised controlled trials in ENL	-	217.634
706.18.39	PUCPR/Functional analysis of candidate variants in the early-onset leprosy phenotype	2.421	5.164
707.19.20	UGM/Implementation Dapsone Hypersensitivity Syndrome, Indonesia/ Nepal	17.304	24.014
707.19.45	DF/Assessing the effectiveness of IECs, Bangladesh	-	21.000
707.19.60	GLRA - NLTB/Collaboration traditional healers, Sierra Leone	-	18.332
707.19.21	BLP/Clofazimine for MB cases at high risk of ENL, Bangladesh/India	21.162	40.726
707.19.64	ALM/LepVax	-	82.500
708.20.04	Oxford Univ./Efficacy and Tolerability of Adjunct Metformin in Multidrug Treatment, Indonesia	22.226	44.452
708.20.09	ICMR/Molecular Mechanisms of Immunomodulation Imparted by MIP vaccine	-	70.938
708.20.12	VU/Informing (generic) approaches to reduce stigma	-	26.937
708.20.14	Leprosy Antimicrobial Resistance Surveillance in PEP Setting, Tanzania (LARS)	-	14.034
708.20.15	RedAid Nigeria/Improving mental health&Quality of Life of Persons affected by Leprosy or Buruli ulcer, Southern Nigeria	28.922	39.040
708.20.17	ENAPAL/ Assessing long-term outcomes & sustainability of family-based approaches, Ethiopia	-	20.321
FP21117	ALM/Assessing Electronic Data Collection Tools, Pathways and HMIS Integration	21.790	13.289
FP2118	NHDP/The Use of Molecular Methods in Subclinical Murine Models of Leprosy	-	5.419
FP21114	VU/Improving management of leprosy reactions and quality of life of persons affected	-	8.411
FP21120	NLR IO/Testing an App supported delivery system for Leprosy Post Exposure Prophylaxis (PEP) services	27.334	46.709
FP21110	LUMC/Point-of-care immunodiagnostic tests	-	68.621
FP21126	Effecthope/Exploring strategies and identifying effective mechanism, Cote d'Ivoire	5.576	-
FP22117	TLM Trust India/Comparison of removable device & total contact cast for healing of ulcer	2.589	7.046
FP2216	TLM Niger/Understanding & Reducing Leprosy-Related Stigma Among Healthcare Workers, Niger	49.993	49.993
FP22121	PLF/ COMBINE: Leprosy elimination by community screening & mass chemoprophylaxis,Kiribati	50.023	50.023
FP2219	RI-MUHC/Identifying drug targets to treat leprosy reactions via genetic susceptibility factors	-	-
FP22119	NLR Nepal/How effective is ongoing SDR-PEP implementation under routine programme conditions	34.517	34.518
FP22115	RedAid Nigeria/Audio & written interventions to improve the perception, knowledge & attitudes towards leprosy	21.145	24.099
FP2218	Erasmus MC/Endgame strategy for leprosy in the Maldives: optimal targeting of PEP	-61	4.880
FP231100016	ICDDR,B/Evaluation of Mycobacterium leprae specific RPA assay	19.270	25.270
FP231100013	Erasmus MC/Leprosy incidence, clustering and risk factors	4.768	4.768
FP231100011	NRC-Myc/Setting an EQA programme for enhancing capacity building	15.000	30.000
FP231100019	TLM Trust India/Addressing healing after multi-drug treatment	18.352	36.704
FP231100017	ICMT/Evaluation of five transcriptomic biomarkers for leprosy	82.850	82.850
FP231100009	ALM/The role of persons affected as agents of change in their community	44.930	44.930
FP231100004	NLR India/Compassion training for reducing stigma & improving quality of care	59.732	54.293
FP231100018	Lepira India/Personalised footwear for foot ulcers in leprosy by baropodometry	30.260	42.127
FP23_CS15	RedAid Nigeria /Collaborative co-design to optimize evidence-based and contextual general health worker training	10.463	10.463
FP23_CS16	INF/Thermographic assessment of autonomic innervation in Leprosy	8.182	8.182
FP24111	Erq Maed/Addressing Leprosy Trauma through the Traumatic Stress Relief Programme	60.545	79.302
FP24119	NLR India/Basic Psychological Support through peer supporters for leprosy & LF	54.258	74.986
FP24121	TLM Nigeria/Capacity Building for Leprosy	42.474	58.214
FP24113	UFMG/Seeking for immunological susceptibility markers for leprosy	28.066	44.224
FP2418	ALM/Use of handheld ultrasound for the early detection of leprosy	68.076	73.396
FP24110	ITM/Role of Drug-resistance and M. lepromatosis in African leprosy transmission	109.791	84.832
FP24112	Lepira Society/Leprosy transmission through WASH and One Health approach	58.392	70.157
Subtotal Research projects		1.040.350	1.782.798
709.00.20	SRC/LRI spring & autumn meetings	113.555	137.000
706.18.99	LRI Workshops	31.127	34.000
709.00.21	Publication costs	2.764	6.000
709.00.22	External audit	11.858	25.000
709.00.23	Internships	-	3.000
Subtotal Other projects		159.304	205.000
Total projects costs		1.199.654	1.987.798

annex V-2

Budget LRI 2025

amounts x €1,000

	Budget 2025	Actuals 2024	Budget 2024
Income			
Income from contributors			
ALM	139	144	144
Damien Foundation	20	35	35
Effect Hope	33	33	34
GLRA/DAHWA	189	194	194
TLM International	139	144	144
Anesvad Foundation	200	200	200
NLR	150	350	350
Other income			
Turing Foundation	366	209	457
Income for co-financed projects	103	73	105
Anesvad Foundation (RESILIENTD projects)	152		
Other amounts	20	10	11
Income in return of goods and services	79	87	68
Sum of income	1.590	1.479	1.742
Expenses			
Research projects costs	1.499	1.041	1.783
Other projects costs	71	159	205
	1.570	1.200	1.988
Running costs	308	293	298
	308	293	298
Sum of expenses	1.878	1.493	2.286
Result	-288	-14	-544

annex V-3

Multi Annual Budget LRI 2025-2027

amounts x €1,000

	Budget 2025	Projection 2026	Projection 2027
Income:			
Income from contributors	870	868	777
Other income	641	608	695
Income in return of goods and services	79	81	83
	<hr/>	<hr/>	<hr/>
Sum of income	1.590	1.557	1.555

	Budget 2025	Projection 2026	Projection 2027
Expenses:			
Research projects costs	1.499	1.322	1.101
Other projects costs	71	183	147
	<hr/>	<hr/>	<hr/>
	1.570	1.505	1.248
Running costs	308	324	338
	<hr/>	<hr/>	<hr/>
	308	324	338
	<hr/>	<hr/>	<hr/>
Sum of expenses	1.878	1.829	1.586
Result	-288	-272	-31

annex V-4 Board and Executives Group of LRI

Board of Directors

	From	Until
Nederlandse Stichting voor Leprabestrijding	01/06/2015	-

Executives Group

The LRI Executives Group (EG) consists of the Executive Directors of the LRI partners.

Ms L. Hummel

Chief Executive Officer; NLR (Chair) 01/01/2021

Mr B. Simmons

President/Chief Executive Officer; American Leprosy Missions

Mr J. Beringer

Chief Executive Officer; German Leprosy Relief Association

Mr B. Morgan

Director; The Leprosy Mission International

Mr I. Lasa

General Director; Anesvad Foundation



LEPROSY RESEARCH INITIATIVE

COLOPHON

Publication: June 2024

The Annual Report of the Leprosy Research Initiative is published on: leprosyresearch.org/about-us/achievements

Cover photo: Medical Camp in Togo. Photo credits to Mario Schmitt, DAHW

Postal address:

P.O. Box 95005
1090 HA Amsterdam

Visiting address:

Wibautstraat 137k
1097 DN Amsterdam

Web:

www.leprosyresearch.org

Email:

info@leprosyresearch.org